Interferon News and Research

RSS

Fingolimod associated with modest, rapid increase in macular volume

Patients with multiple sclerosis treated with fingolimod undergo a modest but rapid increase in macular volume, research shows.

13 Dec 2012

Medivir commences cohort 2 simeprevir and sofosbuvir phase II combination trial in HCV GT1

Medivir AB, announced today the initiation of cohort 2 in the interferon-free phase II trial combining simeprevir with sofosbuvir (GS7977) based on a safety and efficacy planned interim analysis of cohort 1 including prior null responder HCV genotype 1 infected patients without advanced hepatic fibrosis.

13 Dec 2012

Immune dysfunction pinpointed in developmental disorder

Children with neurodevelopmental abnormalities resulting from duplication of the methyl-CpG binding protein 2 gene also have impaired T-helper-cell 1 responses, research shows.

10 Dec 2012

Disturbances in several immune-system-related pathways contribute to development of ASDs

Researchers using novel approaches and methodologies of identifying genes that contribute to the development of autism have found evidence that disturbances in several immune-system-related pathways contribute to development of autism spectrum disorders.

7 Dec 2012

Temsirolimus effective for mRCC patients on hemodialysis

Research findings published in the International Journal of Clinical Oncology suggest that temsirolimus effectively stabilizes disease progression in patients with metastatic renal cell carcinoma undergoing hemodialysis.

22 Nov 2012

GSK receives FDA approval for PROMACTA to treat thrombocytopenia

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved PROMACTA for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy.

19 Nov 2012

Researchers discover health similarities between humans and pigs

An international scientific collaboration that includes two Kansas State University researchers is bringing home the bacon when it comes to potential animal and human health advancements, thanks to successfully mapping the genome of the domestic pig.

17 Nov 2012

Tregs appears to play an important role in suppressing immune response in advance of sepsis

Following an infection, dysregulation of the immune system can result in a systemic inflammatory response and an often fatal condition called severe sepsis or septic shock. Sepsis is not uncommon, yet its cause and underlying immune dysfunction remain poorly understood.

17 Nov 2012

Abbott releases details on phase 3 hepatitis C registrational program

Abbott today released details on its phase 3 hepatitis C registrational program following promising results from its phase 2b clinical trial, known as Aviator, presented at the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) in Boston.

13 Nov 2012

Caution over monoclonal antibody treatment for MS

Alemtuzumab, an anti-CD52 monoclonal antibody, provides a more effective treatment for individuals with relapsing‑remitting multiple sclerosis than the immunomodulating drug interferon beta 1a, but has significant side effects, show findings from a phase III trial.

12 Nov 2012

SCYNEXIS announces results from SCY-635 Phase 2a study on HCV

SCYNEXIS, Inc. today announced that the results of a Phase 2a study of lead candidate SCY-635 for the treatment of the hepatitis C virus (HCV) will be the subject of an oral presentation at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place from November 9-13 in Boston, Massachusetts.

7 Nov 2012

Biologists determine how blind mole rats fight off cancer

Biologists at the University of Rochester have determined how blind mole rats fight off cancer-and the mechanism differs from what they discovered three years ago in another long-lived and cancer-resistant mole rat species, the naked mole rat.

6 Nov 2012

Phase II study to evaluate Medivir/Janssen's simeprevir and Vertex against HCV

Medivir AB, announced today plans for a phase II proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing of Medivir/Janssen's protease inhibitor simeprevir and Vertex's nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135.

3 Nov 2012

Janssen, Vertex to evaluate TMC435 and VX-135 in Phase 2 HCV study

Janssen Pharmaceuticals, Inc. today announced that it has entered into a non-exclusive collaboration with Vertex Pharmaceuticals Incorporated to evaluate in a Phase 2 study the safety and efficacy of an all-oral regimen for the treatment of hepatitis C (HCV).

2 Nov 2012

Multiple sclerosis disease activity reduced by leukaemia drug, even when first-line treatment has failed

A drug which was originally developed to treat leukaemia and other cancers of the immune system offers substantial improvements over existing treatments in reducing relapse rates for people with multiple sclerosis (MS), even when they have not responded well to first-line treatment, according to the results of two phase 3 trials published Online First in The Lancet.

1 Nov 2012

Antiviral therapy cuts progression to cancer in hepatitis

Antiviral therapy may prevent the most common form of liver cancer developing among patients who have hepatitis C-related fibrosis or cirrhosis, report researchers.

25 Oct 2012

Sortilin receptor plays an important role in function of the immune system

To transport substances from the site of their production to their destination, the body needs a sophisticated transport and sorting system. Various receptors in and on the cells recognize certain molecules, pack them and ensure that they are transported to the right place. One of these receptors is Sortilin.

20 Oct 2012

Cytokine levels altered in FEP, schizophrenia patients

Levels of certain cytokines are altered in patients with first-episode psychosis and patients with schizophrenia, research shows.

17 Oct 2012

BioLineRx completes pre-clinical development of BL-8020 for HCV

BioLineRx, a biopharmaceutical development company, announced today that it has successfully completed the pre-clinical development of BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus (HCV), and plans to commence a Phase I/II safety and efficacy study for BL-8020 in Europe during the first quarter of 2013.

17 Oct 2012

FIGHT HLH Consortium receives EUR 6 million FP7 grant for testing NovImmune's NI-0501

NovImmune SA announced that the European Commission has awarded a 6 million Euros FP7 grant to the "FIGHT HLH" consortium of institutions to support clinical testing of NovImmune's anti-interferon gamma drug candidate, NI-0501.

15 Oct 2012